What is the Best Alternative to Ozempic for Weight Loss?

Last reviewed: June 28, 2026

Last updated: June 28, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

The question contains a premise worth correcting before answering it: Ozempic is not approved for weight loss in the first place. According to the Ozempic prescribing information, it is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and to reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. Weight management appears nowhere in that label. So anyone looking for an alternative to Ozempic for weight loss is not looking for a substitute — they are looking for the medications that actually hold a weight-management indication, and several of them do.

Wegovy: The Same Molecule, the Right Indication

Wegovy contains semaglutide, exactly as Ozempic does, but it was developed and approved for weight management. The Wegovy prescribing information indicates the injection, alongside a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 and older with obesity, and in adults with overweight plus at least one weight-related comorbid condition. It is also indicated to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight, and for noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced liver fibrosis.

The evidence is the 68-week STEP 1 trial in 1,961 adults, where mean body weight change was −14.9% with semaglutide 2.4 mg versus −2.4% with placebo. Wegovy's labeled maximum maintenance dosage is now 7.2 mg once weekly, supported by a 72-week trial in 1,407 participants that reported −18.7% at 7.2 mg versus −15.6% at 2.4 mg and −3.9% with placebo. For most people asking this question, Wegovy is the answer to the question they meant to ask.

Zepbound: A Different Molecule With Larger Trial Numbers

Zepbound contains tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist rather than a single-pathway agonist. The Zepbound prescribing information indicates it, with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight with at least one weight-related comorbid condition, and to treat moderate to severe obstructive sleep apnea in adults with obesity.

SURMOUNT-1 randomized 2,539 adults with obesity or overweight, excluding diabetes, to 72 weeks of once-weekly tirzepatide or placebo, reporting mean weight reductions of 15.0%, 19.5% and 20.9% across doses versus 3.1% with placebo. Cross-trial comparisons are imperfect — different populations, different durations, different protocols — but the SURMOUNT and STEP programs are close enough in design that the higher tirzepatide figures are taken seriously. Tirzepatide is also marketed as Mounjaro, which is approved only for glycemic control in type 2 diabetes and carries no weight-management indication.

Oral Options Are Real, But Read the Label Carefully

Tablet formulations now exist across both indications, and confusing them is easy. Wegovy tablets are covered within the Wegovy prescribing information and are indicated for weight reduction and for cardiovascular risk reduction in adults — but they carry only two of the injection's indications, without the pediatric or MASH uses. Rybelsus and Ozempic tablets are oral semaglutide products indicated for type 2 diabetes, not for weight management.

Orforglipron, marketed as Foundayo, was approved on April 1, 2026 and is a small-molecule oral option rather than a peptide. Meanwhile there is no FDA-approved oral tirzepatide and no oral Zepbound, so any product described that way should be treated with suspicion. Which formulation suits a given person depends on tolerability, other medications and clinical history — not on which sounds more convenient.

Older and Non-Incretin Options Still Have a Place

Saxenda, containing liraglutide, remains approved for weight management. The Saxenda prescribing information indicates it, with reduced-calorie diet and increased physical activity, for adults and pediatric patients aged 12 and older with body weight greater than 60 kg and obesity, and for adults with overweight plus at least one weight-related comorbid condition. It is injected once daily rather than weekly, which is a meaningful difference in burden — and its label reports injection site reactions in 13.9% of treated adults versus 10.5% on placebo, considerably higher than the once-weekly products.

Non-incretin oral medications approved for chronic weight management also exist and predate this entire class. They generally produce smaller average reductions, but their side-effect profiles, contraindications and costs differ, and for some people that combination fits better.

What "Best" Actually Depends On

The largest number in a trial is not automatically the right answer for an individual. Contraindications rule options in and out before efficacy is even discussed — the incretin agents carry a boxed warning for risk of thyroid C-cell tumors and are contraindicated with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Pancreatitis history, gallbladder disease, gastrointestinal disease, pregnancy plans and concurrent medications all shape the decision.

Then there is what a person can actually obtain and sustain. Coverage frequently follows the indication rather than the ingredient, which is why a plan may cover semaglutide for diabetes and decline it for weight management. Tolerability matters too: in STEP 1, 4.5% of semaglutide participants discontinued because of gastrointestinal events versus 0.8% on placebo, and a medication nobody stays on produces no result at all.

Where Compounded Preparations Fit — and Where They Do Not

Compounded semaglutide and tirzepatide are not FDA-approved finished products, and the FDA does not review compounded preparations for safety, effectiveness or quality before they are marketed. They are prepared by licensed pharmacies pursuant to a prescription for an individual patient, which is what distinguishes them from material sold to consumers as research chemicals.

They are also not clinically equivalent to the approved brands, and no bioequivalence determination has been made. Wegovy, Ozempic, Zepbound and Mounjaro are the FDA-approved brands; none of them has an approved generic, so no compounded preparation is a generic version of any of them. Being accurate about this is not a technicality — it is the difference between an informed choice and a misinformed one.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

Is Ozempic approved for weight loss?

No. The Ozempic prescribing information indicates it as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and to reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. Weight management is not a labeled indication.

What is the closest approved equivalent for weight management?

Wegovy contains the same active ingredient, semaglutide, and is indicated for weight reduction in adults and pediatric patients aged 12 and older with obesity, and in adults with overweight plus a weight-related comorbid condition. In the 68-week STEP 1 trial of 1,961 adults, mean body weight change was −14.9% with semaglutide 2.4 mg versus −2.4% with placebo. Its labeled maximum maintenance dosage is now 7.2 mg once weekly.

Does Zepbound produce more weight loss than Wegovy?

The trial figures are higher, though cross-trial comparison has limits. SURMOUNT-1 reported mean reductions of 15.0%, 19.5% and 20.9% over 72 weeks in 2,539 adults versus 3.1% with placebo, while STEP 1 reported −14.9% over 68 weeks versus −2.4%. The populations, durations and protocols differ. Which medication is appropriate for a given person depends on contraindications, tolerability, other conditions and access, not on the headline number.

Are there oral alternatives?

Yes, but the labels differ sharply. Wegovy tablets sit within the Wegovy prescribing information and carry weight-reduction and cardiovascular indications for adults, without the injection's pediatric or MASH uses. Rybelsus and Ozempic tablets are oral semaglutide products indicated for type 2 diabetes, not weight management. Orforglipron, marketed as Foundayo, was approved April 1, 2026. There is no FDA-approved oral tirzepatide.

Is compounded semaglutide equivalent to Ozempic or Wegovy?

No. Compounded preparations are not FDA-approved finished products, and the FDA does not review them for safety, effectiveness or quality before marketing. No bioequivalence determination has been made, so describing them as clinically equivalent is inaccurate. They are prepared by licensed pharmacies pursuant to a prescription for an individual patient, and because the approved brands have no approved generics, a compounded preparation is not a generic version of any of them.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.